Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Three New Next Generation Cardiac Marker Products Launched

By LabMedica International staff writers
Posted on 21 Jul 2010
A Swiss company offers three new cardiac marker test kits for point-of-care (POC) settings. More...


The next generation products are Troponin I--a single-analyte, improved sensitivity Troponin I (TnI) test, Cardio2--a two analyte panel consisting of the new Troponin I and B-type natriuretic peptide (BNP), as well as Cardio3--a three analyte panel consisting of the new Troponin I, BNP and Creatine Kinase, Muscle and Brain (CK-MB).

Alere International (Morges, Switzerland) launched the three new cardiac marker test kits. By offering this improved sensitivity troponin assay on panels that simultaneously test other cardiac markers at the POC, these products will allow emergency physicians to make better chest pain/shortness-of-breath patient disposition decisions much more rapidly.

When used in a rapid serial draw algorithm, the panel results can identify healthy patients earlier, allowing them to go home sooner and physicians to focus their time on only those patients in greatest need. All three products are designed for use on the Triage Meter.

The tests are now available for commercial sale in Europe, Australia, and New Zealand and will soon be available in other countries around the world.

Alere is the new global brand adopted by many of the diagnostic and health management businesses of Inverness Medical Innovations (Waltham, MA, USA).

Related Links:
Alere International
Inverness Medical Innovations





New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Urinalysis Solution
UN-9000
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.